Literature DB >> 22207766

A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation.

Flora Tshinanu Musuamba1, Michel Mourad, Vincent Haufroid, Martine Demeyer, Arnaud Capron, Isabelle K Delattre, Frederic Delaruelle, Pierre Wallemacq, Roger Karel Verbeeck.   

Abstract

Mycophenolic acid (MPA) and tacrolimus (TAC) are immunosuppressive agents used in combination with corticosteroids for the prevention of acute rejection after solid organ transplantation. Their pharmacokinetics (PK) show considerable unexplained intraindividual and interindividual variability, particularly in the early period after transplantation. The main objective of the present work was to design a study based on D-optimality to describe the PK of the 2 drugs with good precision and accuracy and to explain their variability by means of patients' demographics, biochemical test results, and physiological characteristics. Pharmacokinetic profiles of MPA and TAC were obtained from 65 stable adult renal allograft recipients on a single occasion (ie, day 15 after transplantation). A sampling schedule was estimated based on the D-optimality criterion with the POPED software, using parameter values from previously published studies on MPA and TAC modeling early after transplantation. Subsequently, a population PK model describing MPA and TAC concentrations was developed using nonlinear mixed-effects modeling. Optimal blood-sampling times for determination of MPA and TAC concentrations were estimated to be at 0 (predose) and at 0.24, 0.64, 0.98, 1.37, 2.38, and 11 hours after oral intake of mycophenolate and TAC. The PK of MPA and TAC were best described by a 2-compartment model with first-order elimination. For MPA, the absorption was best described by a transit compartment model, whereas first-order absorption with a lag time best described TAC transfer from the gastrointestinal tract. Parameters were estimated with good precision and accuracy. While hematocrit levels and CYP3A5 genetic polymorphism significantly influenced TAC clearance, the pharmaceutical formulation and MRP2 genetic polymorphism were retained as significant covariates on MPA absorption and elimination, respectively. The prospective use of the simultaneous D-optimal design approach for MPA and TAC has allowed good estimation of MPA and TAC PK parameters in the early period after transplantation characterized by a very high unexplained variability. The influence of some relevant covariates could be shown.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22207766     DOI: 10.1177/0091270011423661

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  16 in total

1.  External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.

Authors:  Chen-Yan Zhao; Zheng Jiao; Jun-Jun Mao; Xiao-Yan Qiu
Journal:  Br J Clin Pharmacol       Date:  2016-02-26       Impact factor: 4.335

2.  Importance of hematocrit for a tacrolimus target concentration strategy.

Authors:  Elisabet Størset; Nick Holford; Karsten Midtvedt; Sara Bremer; Stein Bergan; Anders Åsberg
Journal:  Eur J Clin Pharmacol       Date:  2013-09-27       Impact factor: 2.953

Review 3.  How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

4.  Population Pharmacokinetics of Mycophenolic Acid: An Update.

Authors:  Tony K L Kiang; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

5.  Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients.

Authors:  Yan Rong; Patrick Mayo; Mary H H Ensom; Tony K L Kiang
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

6.  Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation.

Authors:  Flora T Musuamba; Michel Mourad; Vincent Haufroid; Martine De Meyer; Arnaud Capron; Isabelle K Delattre; Roger K Verbeeck; Pierre Wallemacq
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

Review 7.  Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

9.  Developmental changes of MPA exposure in children.

Authors:  Elisa C Yoo; Ana Catalina Alvarez-Elías; Ekaterina Kirilova Todorova; Guido Filler
Journal:  Pediatr Nephrol       Date:  2016-01-07       Impact factor: 3.714

10.  Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach.

Authors:  Tom M Nanga; Thao T P Doan; Pierre Marquet; Flora T Musuamba
Journal:  Br J Clin Pharmacol       Date:  2019-12-17       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.